SCHEMBL63541

SCHEMBL63541

CN(C)C(=O)C(=O)NC12CCC(CC1)Cn1c2nc(C(=O)NCc2cccc(Cl)c2)c(O)c1=O

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.40
MAPT P10636 1/20 0.37
THRB P10828 1/20 0.37
LMNA P02545 2/20 0.36
KCNH2 Q12809 1/20 0.36
P2RX7 Q99572 1/20 0.36
KMT2A Q03164 2/20 0.36
POLB P06746 1/20 0.35
ROCK2 O75116 1/20 0.35
MEN1 O00255 1/20 0.35
HCRTR1 O43613 1/20 0.35
PDE10A Q9Y233 1/20 0.35
TP53 P04637 2/20 0.35
MAOB P27338 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
NPC1 O15118 1/20 0.34
ALDH1A1 P00352 1/20 0.34
METAP2 P50579 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL62746 0.93 ABCB1 (0.39) CYP2C9THRBLMNAKMT2AMEN1
SCHEMBL64292 0.92 CYP2C9 (0.41) CYP2C9KCNH2
SCHEMBL62751 0.91 CYP2C9 (0.47) CYP2C9MAPTTHRBLMNAKCNH2
SCHEMBL63919 0.91 CYP2C9 (0.46) CYP2C9MAPTTHRBLMNAKCNH2
SCHEMBL53142 0.91 CYP2C9 (0.45) CYP2C9KCNH2KMT2APOLBMEN1
SCHEMBL63590 0.90 LIPG (0.42) CYP2C9KCNH2
SCHEMBL63517 0.90 CYP2C9 (0.42) CYP2C9KCNH2P2RX7
SCHEMBL52913 0.90 CYP2C9 (0.44) CYP2C9KCNH2
SCHEMBL64287 0.90 KMT2A (0.42) CYP2C9MAPTTHRBLMNAKMT2A
SCHEMBL52389 0.89 CYP2C9 (0.39) CYP2C9MAPTKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280981-B1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-04-23 EP disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG CYP2C9 602/4885MAPT 2585/4885THRB 4214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.